Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women

ERC-230 open-label study

Celine Bouchard, Fernand Labrie, Leonard DeRogatis, Ginette Girard, Normand Ayotte, John Christopher G. Gallagher, Leonello Cusan, David F. Archer, David Portman, Lyne Lavoie, Adam Beauregard, Isabelle Côte, Celine Martel, Mario Vaillancourt, John Balser, Erick Moyneur

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Intravaginal DHEA (dehydroepiandrosterone, prasterone), the exclusive precursor of androgens and estrogens in postmenopausal women, has previously been shown to improve all the domains of sexual function by a strictly local action in the vagina. The well recognized female sexual function index (FSFI) questionnaire was used in the present study. Design: The long-term effect of 52-week treatment with daily intravaginal 0.50% (6.5 mg) DHEA was evaluated on the various domains of female sexual function using the FSFI questionnaire at baseline, Week 26 and Week 52. Subjects: One hundred and fifty-four postmenopausal women with at least one mild to severe symptom of vulvovaginal atrophy (VVA) and who have completed the FSFI questionnaire at baseline and at least one post-baseline timepoint were included in the analysis. Results: The FSFI domains desire, arousal, lubrication, orgasm, satisfaction and pain were increased by 28%, 49%, 115%, 51%, 41% and 108%, respectively (p<0.0001 for all parameters) at 52 weeks vs. baseline, while the total score was increased from 13.4±0.62 at baseline to 21.5±0.82 (+60%, p<0.0001) at 52 weeks. Conclusion: As the serum levels of DHEA and all its metabolites, including estradiol and testosterone, show no meaningful change, the present clinical data indicate a stimulatory effect of intravaginal DHEA through a strictly local action in agreement with the preclinical data showing that the androgens made locally from DHEA in the vagina induce an increase in local nerve density.

Original languageEnglish (US)
Pages (from-to)181-190
Number of pages10
JournalHormone Molecular Biology and Clinical Investigation
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Dehydroepiandrosterone
Vagina
Androgens
Orgasm
Lubrication
Arousal
Atrophy
Testosterone
Estradiol
Estrogens
Pain
Serum
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women : ERC-230 open-label study. / Bouchard, Celine; Labrie, Fernand; DeRogatis, Leonard; Girard, Ginette; Ayotte, Normand; Gallagher, John Christopher G.; Cusan, Leonello; Archer, David F.; Portman, David; Lavoie, Lyne; Beauregard, Adam; Côte, Isabelle; Martel, Celine; Vaillancourt, Mario; Balser, John; Moyneur, Erick.

In: Hormone Molecular Biology and Clinical Investigation, Vol. 25, No. 3, 01.03.2016, p. 181-190.

Research output: Contribution to journalArticle

Bouchard, C, Labrie, F, DeRogatis, L, Girard, G, Ayotte, N, Gallagher, JCG, Cusan, L, Archer, DF, Portman, D, Lavoie, L, Beauregard, A, Côte, I, Martel, C, Vaillancourt, M, Balser, J & Moyneur, E 2016, 'Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study', Hormone Molecular Biology and Clinical Investigation, vol. 25, no. 3, pp. 181-190. https://doi.org/10.1515/hmbci-2015-0044
Bouchard, Celine ; Labrie, Fernand ; DeRogatis, Leonard ; Girard, Ginette ; Ayotte, Normand ; Gallagher, John Christopher G. ; Cusan, Leonello ; Archer, David F. ; Portman, David ; Lavoie, Lyne ; Beauregard, Adam ; Côte, Isabelle ; Martel, Celine ; Vaillancourt, Mario ; Balser, John ; Moyneur, Erick. / Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women : ERC-230 open-label study. In: Hormone Molecular Biology and Clinical Investigation. 2016 ; Vol. 25, No. 3. pp. 181-190.
@article{5f2b64b779644ec1a3a8b13f59a7352f,
title = "Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study",
abstract = "Objective: Intravaginal DHEA (dehydroepiandrosterone, prasterone), the exclusive precursor of androgens and estrogens in postmenopausal women, has previously been shown to improve all the domains of sexual function by a strictly local action in the vagina. The well recognized female sexual function index (FSFI) questionnaire was used in the present study. Design: The long-term effect of 52-week treatment with daily intravaginal 0.50{\%} (6.5 mg) DHEA was evaluated on the various domains of female sexual function using the FSFI questionnaire at baseline, Week 26 and Week 52. Subjects: One hundred and fifty-four postmenopausal women with at least one mild to severe symptom of vulvovaginal atrophy (VVA) and who have completed the FSFI questionnaire at baseline and at least one post-baseline timepoint were included in the analysis. Results: The FSFI domains desire, arousal, lubrication, orgasm, satisfaction and pain were increased by 28{\%}, 49{\%}, 115{\%}, 51{\%}, 41{\%} and 108{\%}, respectively (p<0.0001 for all parameters) at 52 weeks vs. baseline, while the total score was increased from 13.4±0.62 at baseline to 21.5±0.82 (+60{\%}, p<0.0001) at 52 weeks. Conclusion: As the serum levels of DHEA and all its metabolites, including estradiol and testosterone, show no meaningful change, the present clinical data indicate a stimulatory effect of intravaginal DHEA through a strictly local action in agreement with the preclinical data showing that the androgens made locally from DHEA in the vagina induce an increase in local nerve density.",
author = "Celine Bouchard and Fernand Labrie and Leonard DeRogatis and Ginette Girard and Normand Ayotte and Gallagher, {John Christopher G.} and Leonello Cusan and Archer, {David F.} and David Portman and Lyne Lavoie and Adam Beauregard and Isabelle C{\^o}te and Celine Martel and Mario Vaillancourt and John Balser and Erick Moyneur",
year = "2016",
month = "3",
day = "1",
doi = "10.1515/hmbci-2015-0044",
language = "English (US)",
volume = "25",
pages = "181--190",
journal = "Hormone Molecular Biology and Clinical Investigation",
issn = "1868-1883",
publisher = "Walter de Gruyter GmbH",
number = "3",

}

TY - JOUR

T1 - Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women

T2 - ERC-230 open-label study

AU - Bouchard, Celine

AU - Labrie, Fernand

AU - DeRogatis, Leonard

AU - Girard, Ginette

AU - Ayotte, Normand

AU - Gallagher, John Christopher G.

AU - Cusan, Leonello

AU - Archer, David F.

AU - Portman, David

AU - Lavoie, Lyne

AU - Beauregard, Adam

AU - Côte, Isabelle

AU - Martel, Celine

AU - Vaillancourt, Mario

AU - Balser, John

AU - Moyneur, Erick

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective: Intravaginal DHEA (dehydroepiandrosterone, prasterone), the exclusive precursor of androgens and estrogens in postmenopausal women, has previously been shown to improve all the domains of sexual function by a strictly local action in the vagina. The well recognized female sexual function index (FSFI) questionnaire was used in the present study. Design: The long-term effect of 52-week treatment with daily intravaginal 0.50% (6.5 mg) DHEA was evaluated on the various domains of female sexual function using the FSFI questionnaire at baseline, Week 26 and Week 52. Subjects: One hundred and fifty-four postmenopausal women with at least one mild to severe symptom of vulvovaginal atrophy (VVA) and who have completed the FSFI questionnaire at baseline and at least one post-baseline timepoint were included in the analysis. Results: The FSFI domains desire, arousal, lubrication, orgasm, satisfaction and pain were increased by 28%, 49%, 115%, 51%, 41% and 108%, respectively (p<0.0001 for all parameters) at 52 weeks vs. baseline, while the total score was increased from 13.4±0.62 at baseline to 21.5±0.82 (+60%, p<0.0001) at 52 weeks. Conclusion: As the serum levels of DHEA and all its metabolites, including estradiol and testosterone, show no meaningful change, the present clinical data indicate a stimulatory effect of intravaginal DHEA through a strictly local action in agreement with the preclinical data showing that the androgens made locally from DHEA in the vagina induce an increase in local nerve density.

AB - Objective: Intravaginal DHEA (dehydroepiandrosterone, prasterone), the exclusive precursor of androgens and estrogens in postmenopausal women, has previously been shown to improve all the domains of sexual function by a strictly local action in the vagina. The well recognized female sexual function index (FSFI) questionnaire was used in the present study. Design: The long-term effect of 52-week treatment with daily intravaginal 0.50% (6.5 mg) DHEA was evaluated on the various domains of female sexual function using the FSFI questionnaire at baseline, Week 26 and Week 52. Subjects: One hundred and fifty-four postmenopausal women with at least one mild to severe symptom of vulvovaginal atrophy (VVA) and who have completed the FSFI questionnaire at baseline and at least one post-baseline timepoint were included in the analysis. Results: The FSFI domains desire, arousal, lubrication, orgasm, satisfaction and pain were increased by 28%, 49%, 115%, 51%, 41% and 108%, respectively (p<0.0001 for all parameters) at 52 weeks vs. baseline, while the total score was increased from 13.4±0.62 at baseline to 21.5±0.82 (+60%, p<0.0001) at 52 weeks. Conclusion: As the serum levels of DHEA and all its metabolites, including estradiol and testosterone, show no meaningful change, the present clinical data indicate a stimulatory effect of intravaginal DHEA through a strictly local action in agreement with the preclinical data showing that the androgens made locally from DHEA in the vagina induce an increase in local nerve density.

UR - http://www.scopus.com/inward/record.url?scp=84979463991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979463991&partnerID=8YFLogxK

U2 - 10.1515/hmbci-2015-0044

DO - 10.1515/hmbci-2015-0044

M3 - Article

VL - 25

SP - 181

EP - 190

JO - Hormone Molecular Biology and Clinical Investigation

JF - Hormone Molecular Biology and Clinical Investigation

SN - 1868-1883

IS - 3

ER -